Discover 3 US Penny Stocks With Market Caps Over $200M

As the U.S. stock market experiences a mixed performance, with the Dow Jones Industrial Average gaining for its fifth straight session while other indices falter, investors are exploring diverse opportunities. Penny stocks, often considered speculative investments due to their low price point and smaller market presence, can still offer significant potential when backed by strong financials. In this article, we will explore several penny stocks that stand out for their financial strength and potential for long-term growth in today's dynamic market landscape.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
Inter & Co (NasdaqGS:INTR)	$4.30	$1.85B	★★★★☆☆
QuantaSing Group (NasdaqGM:QSG)	$3.08	$103.25M	★★★★★★
BAB (OTCPK:BABB)	$0.84	$6.43M	★★★★★★
Pangaea Logistics Solutions (NasdaqCM:PANL)	$4.90	$234.98M	★★★★★☆
ZTEST Electronics (OTCPK:ZTST.F)	$0.25	$8.83M	★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)	$2.85	$86.14M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$67.38M	★★★★★★
BTCS (NasdaqCM:BTCS)	$2.59	$49.54M	★★★★★★
Smith Micro Software (NasdaqCM:SMSI)	$1.62	$22.53M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.9125	$76.47M	★★★★★☆

Click here to see the full list of 732 stocks from our US Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

CureVac (NasdaqGM:CVAC)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: CureVac N.V. is a biopharmaceutical company specializing in the development of transformative mRNA-based medicines, with a market cap of approximately $684.16 million.

Operations: The company's revenue is primarily generated from the discovery and development of biotechnological applications, amounting to €65.86 million.

Market Cap: $684.16M

CureVac N.V., with a market cap of approximately $684.16 million, remains a speculative investment in the biotech sector due to its pre-revenue status and unprofitability. The company has faced increasing losses over the past five years, yet it operates debt-free and has not diluted shareholders recently. CureVac's short-term assets comfortably cover both its short- and long-term liabilities, but it faces challenges with less than a year of cash runway based on current free cash flow. Recent executive changes include appointing Axel Sven Malkomes as CFO, potentially signaling strategic shifts as the company seeks growth opportunities.

• Navigate through the intricacies of CureVac with our comprehensive balance sheet health report here.
• Learn about CureVac's future growth trajectory here.

Stitch Fix (NasdaqGS:SFIX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Stitch Fix, Inc. operates an online platform offering apparel, shoes, and accessories for various demographics in the United States with a market cap of approximately $478.20 million.

Operations: The company's revenue is primarily generated through its online retail segment, which amounted to $1.29 billion.

Market Cap: $478.2M

Stitch Fix, Inc., with a market cap of approximately US$478.20 million, presents a mixed picture in the penny stock landscape. Despite being unprofitable and experiencing increased losses over the past five years, it operates without debt and maintains sufficient cash runway for over three years. The company has experienced shareholder dilution recently but remains financially stable with short-term assets exceeding liabilities. Recent developments include its addition to the S&P Retail Select Industry Index and providing revenue guidance for fiscal 2025, projecting net revenue between US$1.14 billion and US$1.18 billion despite declining sales from previous quarters.

• Jump into the full analysis health report here for a deeper understanding of Stitch Fix.
• Understand Stitch Fix's earnings outlook by examining our growth report.

Zevia PBC (NYSE:ZVIA)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Zevia PBC is a beverage company that develops, markets, sells, and distributes various carbonated beverages in the United States and Canada, with a market cap of $254.82 million.

Operations: The company's revenue is primarily generated from its non-alcoholic beverages segment, amounting to $153.39 million.

Market Cap: $254.82M

Zevia PBC, with a market cap of US$254.82 million, is navigating the penny stock environment with some challenges and strengths. The company remains unprofitable, with increasing losses over the past five years and no forecasted profitability in the near term. Despite this, Zevia is debt-free and boasts a cash runway sufficient for over three years based on current free cash flow. Recent earnings showed a decrease in sales to US$36.37 million for Q3 2024 compared to last year, but net losses have narrowed. Shareholders experienced dilution as shares outstanding increased by 2.3% over the past year.

• Unlock comprehensive insights into our analysis of Zevia PBC stock in this financial health report.
• Assess Zevia PBC's future earnings estimates with our detailed growth reports.

Make It Happen

• Embark on your investment journey to our 732 US Penny Stocks selection here.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com